GlassScriptPhysician profile
Catherine J Gordon
NPI 1346349487
$1,369.66
in general payments reported to CMS, 2019-2025
17 companies · $74.38 in 2025
The $74.38 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $200 · 2021: $17.99 · 2022: $125 · 2023: $380 · 2024: $122 · 2025: $74.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $348.69 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $225.13 | 2019-2024 | |
| Novo Nordisk INC | $145.06 | 2019-2020 | |
| Shire North American Group INC | $134.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $128.10 | 2019-2023 | |
| Pfizer INC. | $79.28 | 2019-2025 | |
| Csl Behring | $48.53 | 2020-2024 | Idelvion |
| Servier Pharmaceuticals LLC | $47.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $35.90 | 2024-2025 | Prevymis |
| Adaptive Biotechnologies Corporation | $35.37 | 2024 | Clonoseq |
| Amgen INC. | $35.36 | 2019 | |
| Rare Disease Therapeutics, INC. | $24.28 | 2025 | Xromi |
| Alexion Pharmaceuticals, INC. | $18.97 | 2024 | Koselugo |
| Emmaus Medical, INC. | $16.91 | 2019 | |
| Adma Biomanufacturing LLC | $16.70 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $16.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.